Latest news with #MaashitlaSecurities
Economic Times
09-07-2025
- Business
- Economic Times
Asston Pharmaceuticals IPO opens for subscription with decent GMP. Check details
The IPO of Asston Pharmaceuticals, a fast-growing exporter of healthcare and pharmaceutical products, opened for public subscription today. The book-built issue is priced in the range of Rs 115 to Rs 123 per share, with a fixed lot size of 1,000 shares. At the upper end of the price band, the IPO seeks to raise Rs 27.56 crore entirely through a fresh issue of 22.41 lakh equity shares. ADVERTISEMENT The IPO has stirred moderate interest in the grey market, where it is commanding a GMP of Rs 15 over the upper issue price of Rs 123 -- a 12% premium. The offer will close on July 11, and the allotment is expected to be finalized on July 14. The stock is scheduled to list on the BSE SME platform on July 16. Retail investors are required to apply for a minimum of 2,000 shares. The lead manager to the issue is Sobhagya Capital Options, while Maashitla Securities is the registrar. JSK Securities and Services will act as the market in 2019, Asston Pharmaceuticals specializes in the formulation and export of a diverse range of pharmaceutical products, including tablets, capsules, syrups, and company caters to multiple therapeutic categories such as antibiotics, antifungals, analgesics, and nutritional supplements. Its manufacturing facilities are FDA-certified and operate under rigorous quality management protocols. ADVERTISEMENT The IPO proceeds are intended to fund capital expenditure for machinery acquisition (Rs 6 crore), meet incremental working capital needs (Rs 13 crore), partially repay borrowings (Rs 1 crore), and cover general corporate the company has shown strong momentum. For the year ended March 2025, Asston posted a 62% rise in revenue and a 218% jump in profit after tax compared to the previous fiscal. ADVERTISEMENT The company reported a PAT of Rs 4.33 crore on revenue of Rs 25.61 crore. (Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times) (You can now subscribe to our ETMarkets WhatsApp channel)
Time of India
09-07-2025
- Business
- Time of India
Asston Pharmaceuticals IPO opens for subscription with decent GMP. Check details
The IPO of Asston Pharmaceuticals, a fast-growing exporter of healthcare and pharmaceutical products , opened for public subscription today. The book-built issue is priced in the range of Rs 115 to Rs 123 per share, with a fixed lot size of 1,000 shares. At the upper end of the price band, the IPO seeks to raise Rs 27.56 crore entirely through a fresh issue of 22.41 lakh equity shares. The IPO has stirred moderate interest in the grey market, where it is commanding a GMP of Rs 15 over the upper issue price of Rs 123 -- a 12% premium. The offer will close on July 11, and the allotment is expected to be finalized on July 14. The stock is scheduled to list on the BSE SME platform on July 16. Retail investors are required to apply for a minimum of 2,000 shares. The lead manager to the issue is Sobhagya Capital Options, while Maashitla Securities is the registrar. JSK Securities and Services will act as the market maker. Founded in 2019, Asston Pharmaceuticals specializes in the formulation and export of a diverse range of pharmaceutical products, including tablets, capsules, syrups, and sachets. The company caters to multiple therapeutic categories such as antibiotics, antifungals, analgesics, and nutritional supplements. Its manufacturing facilities are FDA-certified and operate under rigorous quality management protocols. The IPO proceeds are intended to fund capital expenditure for machinery acquisition (Rs 6 crore), meet incremental working capital needs (Rs 13 crore), partially repay borrowings (Rs 1 crore), and cover general corporate expenses. Financially, the company has shown strong momentum. For the year ended March 2025, Asston posted a 62% rise in revenue and a 218% jump in profit after tax compared to the previous fiscal. The company reported a PAT of Rs 4.33 crore on revenue of Rs 25.61 crore. ( Disclaimer : Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times) ETMarkets WhatsApp channel )
Time of India
30-06-2025
- Business
- Time of India
Marc Loire Fashions IPO opens for subscription. Check price band, issue size and other key details
Marc Loire Fashions is launching its IPO today. The company plans to raise Rs 21 crore. It will offer 21 lakh equity shares at Rs 100 each. Marc Loire Fashions launches its IPO today, aiming to raise ₹21 crore through a fixed price issue. The women's footwear company will use the funds to expand its retail presence with 15 new outlets and support working capital. With a strong financial performance, including a PAT margin of 11. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads The initial public offering (IPO) of Marc Loire Fashions will open for public subscription today and will remain open until Wednesday. The company aims to raise Rs 21 crore through a fixed price issue of 21 lakh equity shares at Rs 100 per share. The listing of shares is expected on the BSE SME platform on July can bid for a minimum of 1,200 equity shares, requiring an investment of Rs 1,20, issue consists entirely of a fresh issue of shares, with no offer-for-sale component. Of the total shares offered, 47.49% are reserved for retail investors and 47.49% for non-institutional Management Services is the lead manager for the issue and Maashitla Securities is serving as the in 2014, Marc Loire Fashions operates in the women's footwear segment, offering a diverse product portfolio that includes ethnic sandals, wedges, formal sandals, athleisure slip-ons, and company markets its products through both Direct-to-Consumer (D2C) online platforms and Business-to-Business (B2B) retail channels, with partnerships across well-known outlets such as Reliance Centro Stores and Lulus Mall, in addition to various e-commerce company has shown stable financial growth with FY25 revenue of Rs 42.46 crore and net profit of Rs 4.71 crore, reflecting an 11.08% PAT margin and a return on equity (ROE) of 44%.Proceeds from the IPO will be used to expand its retail footprint through the launch of 15 new exclusive brand outlets, fund working capital needs, purchase display infrastructure, and cover general corporate results are expected by Thursday, July 3, followed by refunds and demat credit by Friday, July 4.: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
Economic Times
30-06-2025
- Business
- Economic Times
Marc Loire Fashions IPO opens for subscription. Check price band, issue size and other key details
The initial public offering (IPO) of Marc Loire Fashions will open for public subscription today and will remain open until Wednesday. The company aims to raise Rs 21 crore through a fixed price issue of 21 lakh equity shares at Rs 100 per share. The listing of shares is expected on the BSE SME platform on July 7. ADVERTISEMENT Investors can bid for a minimum of 1,200 equity shares, requiring an investment of Rs 1,20,000. The issue consists entirely of a fresh issue of shares, with no offer-for-sale component. Of the total shares offered, 47.49% are reserved for retail investors and 47.49% for non-institutional investors. Finshore Management Services is the lead manager for the issue and Maashitla Securities is serving as the in 2014, Marc Loire Fashions operates in the women's footwear segment, offering a diverse product portfolio that includes ethnic sandals, wedges, formal sandals, athleisure slip-ons, and company markets its products through both Direct-to-Consumer (D2C) online platforms and Business-to-Business (B2B) retail channels, with partnerships across well-known outlets such as Reliance Centro Stores and Lulus Mall, in addition to various e-commerce platforms. ADVERTISEMENT The company has shown stable financial growth with FY25 revenue of Rs 42.46 crore and net profit of Rs 4.71 crore, reflecting an 11.08% PAT margin and a return on equity (ROE) of 44%.Proceeds from the IPO will be used to expand its retail footprint through the launch of 15 new exclusive brand outlets, fund working capital needs, purchase display infrastructure, and cover general corporate expenses. ADVERTISEMENT Allotment results are expected by Thursday, July 3, followed by refunds and demat credit by Friday, July 4. (Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times) (You can now subscribe to our ETMarkets WhatsApp channel)
&w=3840&q=100)
Business Standard
25-06-2025
- Business
- Business Standard
Influx Healthtech lists at 38% premium on NSE SME, beats GMP estimates
Influx Healthtech IPO listing today: Shares of healthcare-focused contract manufacturer Influx Healthtech made a robust market debut on Wednesday, June 25, 2025, listing at ₹132.5 on the NSE SME platform, a premium of 38 per cent from its issue price of ₹96 per share. After the listing, shares of Influx Healthtech were trading at 127.5, down 3.77 per cent from the opening price. Influx Healthtech debut was significantly above the grey market expectations. Ahead of listing, the unlisted shares of Influx Healthtech were trading ₹116, reflecting a premium of ₹20 or 20.8 per cent against the issue price. Influx Healthtech IPO subscription The company offered shares in the price band of ₹91 to ₹96 with a lot size of 1,200 shares. It received bids for 81,75,38,400 shares against the 40,58,400 shares offered, resulting in an oversubscription of 201 times by the end of the subscription period, showed NSE data. Influx Healthtech IPO details Influx Healthtech IPO was combination of fresh issue of 5 million equity shares to raise ₹48 crore and offer for sale (OFS) of 1.1 million equity shares aggregating to ₹10.56 crore. Influx Healthtech IPO was available for subscription from Wednesday, June 18, 2025, till Friday, June 20, 2025. The basis of allotment of shares was finalised on Monday, June 23, 2025. Maashitla Securities was the registrar of the issue. Rarever Financial Advisors was the book-running lead manager of the Influx Healthtech IPO. According to the red herring prospectus (RHP), the company plans to use the net fresh issue proceeds to set up a manufacturing facility for Nutraceutical Division, another manufacturing facility for Veterinary Food Division, and purchase of machinery for homecase and cosmetic division. The remaining funds will be used for general corporate purposes. About Influx Healthtech Incorporated in 2020, Influx Healthtech is a Mumbai-based, healthcare-focused company specialising in contract manufacturing. The company operates three manufacturing units in Thane, Maharashtra. The company's expertise spans the production of Dietary and Nutritional Supplements, Cosmetics, Ayurvedic/Herbal Products, Veterinary Feed Supplements, Homecare Products, Active Pharmaceutical Ingredients (API), and finished dosage forms, including tablets, capsules and injectables.
